Navigation Links
Synthetic Biologics' SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
Date:11/14/2013

ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today announced that SYN-004, Synthetic Biologics' product candidate for the prevention of C. difficile infections, was selected as a 2013 Top Project to Watch in the infectious disease area. This selection was made through Elsevier Business Intelligence's panel of independent experts who screen hundreds of compounds and weigh their potential as future products. The Company also announced that Jeffrey Riley, CEO, will present at the 2013 Therapeutic Area Partnerships Conference on Tuesday, November 19, 2013 at 4:00pm (EST) at the Hyatt Regency in Boston.

(Logo:  http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with conference attendees on Tuesday and Wednesday, November 19 and 20, 2013.

About Elsevier Business Intelligence and the Therapeutic Area Partnerships Conference

Elsevier Business Intelligence provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing a combination of news and information together with penetrating insight and analysis.

Organized by Elsevier Business Intelligence, the 2013 Therapeutic Area Partnerships (TAP) conference is designed to bring together biopharmaceutical industry decision makers to assess the most promising drug programs available for partnering in the following therapeutic areas: oncology, cardiovascular/metabolic diseases, neuroscience, infectious diseases, anti-inflammatory/autoimmune diseases and advanced therapies. For more information, please visit the conference website at http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.

About Synthetic Biologics, Inc.

Synthetic Biologics (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
2. China Synthetic Resin Industry Report, 2013-2016
3. Synthetic Biologics to Report Third Quarter 2013 Financial Results
4. Atlantic Peptides, a Synthetic Peptide Manufacturer, Unveils Its New Website for Easier Navigation
5. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
6. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
7. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
8. Synthetic Biologics to Report Second Quarter 2013 Financial Results
9. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
10. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
11. Synthetic Biologics to Present at OneMedForum New York 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... the World Technology Awards. uBiome is one of just six company finalists in ... , In addition to uBiome, companies nominated as finalists in this year’s awards ...
(Date:12/8/2016)... 8, 2016 Savannah River Remediation LLC ... selected NewTechBio,s NT-MAX Lake & Pond Sludge ... bacteria, in conjunction with Hexa Armor/ Rhombo cover ... National Pollutant Discharge Elimination System requirements. ... steady history of elevated pH levels, above 8.5, ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published ... of previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate ... timing of blood sampling may improve the value of a blood-based test.” The ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/5/2016)... Dec. 5, 2016  The Office of Justice ... "Can CT Scans Enhance or Replace Medico Legal ... of supporting or replacing forensic autopsies with postmortem ... In response to recommendations made by ... using CT scans as a potential component of ...
Breaking Biology News(10 mins):